FMC Sylacauga is a medicare approved dialysis facility center in Sylacauga, Alabama and it has 12 dialysis stations. It is located in Talladega county at 314 West Spring Street, Sylacauga, AL, 35150. You can reach out to the office of FMC Sylacauga at (256) 249-9660. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Sylacauga has the following ownership type - Profit. It was first certified by medicare in July, 1996. The medicare id for this facility is 012566 and it accepts patients under medicare ESRD program.
Name | FMC Sylacauga |
---|---|
Location | 314 West Spring Street, Sylacauga, Alabama |
No. of Dialysis Stations | 12 |
Medicare ID | 012566 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
314 West Spring Street, Sylacauga, Alabama, 35150 | |
(256) 249-9660 | |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
NPI Number | 1558473397 |
Organization Name | Rcg Sylacauga |
Doing Business As | Nna Of Alabama Inc |
Address | 314 W Spring St Sylacauga, Alabama, 35150 |
Phone Number | (256) 249-9660 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
Dialysis patients with Hemoglobin data | 26 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 54 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 441 |
Percentage of adult patients getting regular hemodialysis at the center | 97 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Sylacauga with elevated calcium levels.
Patients with hypercalcemia | 56 |
Hypercalcemia patient months | 465 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
Patients with Serumphosphor | 59 |
Patients with Serumphosphor less than 3.5 mg/dL | 5 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 27 |
Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 44 |
Patient months included in arterial venous fistula and catheter summaries | 359 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 55 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 37 |
Hospitalization Rate in facility | 165.1 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 323.9 |
Hospitalization Rate: Lower Confidence Limit | 88.7 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Sylacauga were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 27.2 (As Expected) |
Readmission Rate: Upper Confidence Limit | 42.4 |
Readmission Rate: Lower Confidence Limit | 15.5 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
Researchers have published results of the largest trial of omega-3 to date, demonstrating a role for omega-3 supplements in lowering the risk of heart attack and CVD.
Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.
AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced that is has been selected as a finalist in the 2010 Colorado Ethics in Business Alliance (CEBA) Awards, in the Samaritan Institute category honoring non-profits.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.
› Verified 6 days ago